Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907033 · ClinicalTrials.gov registry record · Phase 4
Liposomal Bupivacaine in Vaginal Hysterectomy
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT03907033: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT03907033 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03907033, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
The aim of this study is to compare the effects of preemptive analgesia using liposomal bupivacaine mixed with bupivacaine HCl, versus bupivacaine HCl alone for uterosacral ligament injection in patients undergoing vaginal hysterectomy. We hypothesize that the group receiving a combination of liposomal bupivacaine and bupivacaine HCl will report superior postoperative pain management. Enhancement in pain control should confer a decrease in opioid and other analgesic medication requirements, which may contribute to decreased nausea, vomiting, and higher overall patient satisfaction with pain control.
Interventions
- DRUG Liposomal bupivacaine
- DRUG Bupivacaine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2021-07-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907033
The ClinicalTrials.gov registry entry for NCT03907033 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine is the first listed.
NCT03907033 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03907033 about?
NCT03907033 is a clinical study titled "Liposomal Bupivacaine in Vaginal Hysterectomy". The aim of this study is to compare the effects of preemptive analgesia using liposomal bupivacaine mixed with bupivacaine HCl, versus bupivacaine HCl alone for uterosacral ligament injection in patients undergoing vaginal hysterectomy. We hypothesize that the group receiving a combination of liposo...
What is the current status of trial NCT03907033?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2019-09-03. Estimated completion is 2021-07-23.
What interventions are being tested in trial NCT03907033?
The interventions under investigation include: Liposomal bupivacaine (DRUG), Bupivacaine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03907033?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.